Insulin lispro

Should be taken with food. Administer w/in 15 min before or immediately after meals.

Hypersensitivity. Episodes of hypoglycaemia.

Patient at risk for hypokalaemia (e.g. receiving loop diuretics). Early warning symptoms of hypoglycaemia may be different or less pronounced in patients with long-standing diabetes, intensified insulin therapy, diabetic nerve disease, or in those who switched from animal-source insulin to human insulin. Renal and hepatic impairment. Children. Pregnancy and lactation. Concomitant use with peroxisome proliferator-activated receptor (PPAR)-γ agonists (including thiazolidinediones). Patient Counselling This drug may impair the ability to concentrate and react as a result of hypoglycaemia; if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood glucose (usually before meals and snacks and at bedtime; additional monitoring if needed); electrolytes, HbA_1c (at least twice yearly in patients who are meeting treatment goals and have stable glycaemic control; quarterly for those who are not meeting treatment goals or with change in therapy); renal and hepatic function, weight.

Significant: Hypoglycaemia, hypokalaemia; lipodystrophy and cutaneous amyloidosis at the inj site. Gastrointestinal disorders: Diarrhoea, nausea, abdominal pain. General disorders and administration site conditions: Inj site reaction (e.g. redness, itching, swelling), flu-like symptoms, pain, oedema. Immune system disorders: Antibody development. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Cough, nasopharyngitis, rhinitis, pharyngitis.
Potentially Fatal: Severe hypoglycaemia, hypersensitivity reactions (including anaphylaxis).

May decrease efficacy with oral contraceptives, corticosteroids, β₂ stimulants (e.g. ritodrine, terbutaline, salbutamol), thyroid hormones, danazol, diuretics, growth hormone. May increase risk of hypoglycaemia with other antidiabetic agents, salicylates (e.g. aspirin), sulfa antibiotics, certain ACE inhibitors (e.g. enalapril, captopril), angiotensin II receptor blockers, β-blockers, certain antidepressants (e.g. MAOIs, SSRIs), somatostatin analogues (e.g. octreotide), pramlintide. May cause dose-related fluid retention which may lead to or exacerbate cardiac failure with PPAR-γ agonists including thiazolidinediones (e.g. pioglitazone). Signs and symptoms of hypoglycaemia may be blunted by β-blockers.

Insulin Preparations

A10AB04 - insulin lispro ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
A10AC04 - insulin lispro ; Belongs to the class of intermediate-acting insulins and analogues. Used in the treatment of diabetes.
A10AD04 - insulin lispro ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.